Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
ARYA Sciences Acquisition III (ARYA)
Upcoming IPO
Vistas Media Acquisition (VMACU)
Hitek Global (HKIT)
Presidio Property Trust (SQFT)
PainReform (PRFX)
PaxMedica (PXMD)
NETSTREIT Corp. (NTST)
Duck Creek Technologies, Inc. (DCT)
Priced IPO
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
Rackspace Technology, Inc. (RXT)
BigCommerce Holdings, Inc (BIGC)
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
Jamf Holding Corp. (JAMF)
Renalytix AI plc (RNLX)
Berkeley Lights, Inc. (BLI)
More companies

Fusion Pharmaceuticals Inc. (FUSN)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. They have developed their Targeted Alpha Therapies, or TAT, platform together with their proprietary Fast-Clear linker technology to enable them to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Their TAT platform is underpinned by their research and insights into the underlying biology of alpha emitting radiopharmaceuticals as well as their differentiated capabilities in target identification, candidate generation, manufacturing and supply chain and development of imaging diagnostics. They believe that their TATs have the potential to build on the successes of currently available radiopharmaceuticals and be broadly applicable across multiple targets and tumor types. Their lead product candidate, FPI-1434, utilizes their Fast-Clear linker to connect a humanized monoclonal antibody that targets the insulin-like growth factor 1 receptor, or IGF-1R, with the alpha emitting isotope actinium-225, or 225Ac. IGF-1R is a well-established tumor target that is found on numerous types of cancer cells, but historical attempts to suppress tumors by inhibiting the IGF-1R signaling pathway have been unsuccessful in the clinic. They are currently conducting a Phase 1 clinical trial of FPI-1434 as a monotherapy in patients with solid tumors expressing IGF-1R and plan to report initial data from the dose escalation portion of this trial approximately three to six months after they fully resume clinical activities following operating disruptions caused by COVID-19.
Industry
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
CEO CFO
John Valliant John Crowley
Employees Founded
40 2014

Contacts

Address: 270 Longwood Road South, Hamilton, ON, L8P 0A6

Telephone: (289) 799-0891

Web page: http://www.fusionpharma.com

IPO information

Expected Date 6/26/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $625
Revenues (MM) $0
Net Income (Loss) (MM) $-23.9

Voting

What do you think will happen with the FUSN share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 8.4
Shares Revised (MM) 12.5
Expected offer amount (MM) $187.5
Realized offer amount(MM) $212.5
Underwriters
Morgan Stanley/ Jefferies/ Cowen
CO-Managers
Wedbush PacGrow

Sector: Healthcare

Tweets about $FUSN

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats